The Claim
Subcutaneous administration of bimagrumab at 525 mg every 4 weeks for 12 weeks results in equivalent changes in fat mass and lean mass compared to intravenous administration of the same dose and schedule, and is associated with a lower incidence of adverse events.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When bimagrumab is injected under the skin instead of into a vein at a dose of 525 mg every four weeks for 12 weeks, it reduces fat mass and increases lean mass to the same degree as the intravenous route, while causing fewer side effects.
See the scientific wording
Subcutaneous administration of bimagrumab at 525 mg every 4 weeks for 12 weeks produces similar reductions in fat mass and increases in lean mass as intravenous dosing, with fewer adverse events, suggesting a viable alternative route of delivery.
Bimagrumab binds to specific receptors on muscle and fat cells, blocking signals that normally limit muscle growth and promote fat storage. This allows muscle cells to build more protein and grow larger, while fat cells stop storing excess fat and break down existing fat deposits, leading to more muscle and less fat without changes in eating habits.
What the research says
1 studyThe study found that injecting bimagrumab under the skin worked just as well as giving it through an IV drip to reduce fat and build muscle, and caused fewer side effects like diarrhea and muscle spasms.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.